sab-185
Biologicalexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 5, 2020 (NCT04468958)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095291 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04469179 | Phase 1 | Aug 20, 2020 | Department of Health and Human Services, ICON, SAB Biotherapeutics |
| NCT04468958 | Phase 1 | Aug 5, 2020 | Department of Health and Human Services, ICON, SAB Biotherapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2020 |
| ICON | For profit | 2 | 0 | 1 | 2020 |
| SAB Biotherapeutics | For profit | 2 | 2 | 1 | 2020 |
3 organizations
Page 1 / 1